These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The fluoroquinolones for urinary tract infections: a review. Cunha BA Adv Ther; 1994; 11(6):277-96. PubMed ID: 10150268 [TBL] [Abstract][Full Text] [Related]
3. Systemic quinolone antibiotics in children: a review of the use and safety. Grady RW Expert Opin Drug Saf; 2005 Jul; 4(4):623-30. PubMed ID: 16011441 [TBL] [Abstract][Full Text] [Related]
4. Current antibiotic therapy for isolated urinary tract infections in women. Kallen AJ; Welch HG; Sirovich BE Arch Intern Med; 2006 Mar; 166(6):635-9. PubMed ID: 16567602 [TBL] [Abstract][Full Text] [Related]
5. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. Ferech M; Coenen S; Malhotra-Kumar S; Dvorakova K; Hendrickx E; Suetens C; Goossens H; J Antimicrob Chemother; 2006 Aug; 58(2):423-7. PubMed ID: 16735418 [TBL] [Abstract][Full Text] [Related]
6. New quinolone antibiotics: a survey of the literature from 2005 to 2010. Wiles JA; Bradbury BJ; Pucci MJ Expert Opin Ther Pat; 2010 Oct; 20(10):1295-319. PubMed ID: 20645884 [TBL] [Abstract][Full Text] [Related]
7. Development of the quinolones. Andersson MI; MacGowan AP J Antimicrob Chemother; 2003 May; 51 Suppl 1():1-11. PubMed ID: 12702698 [TBL] [Abstract][Full Text] [Related]
8. Prulifloxacin: a new antibacterial fluoroquinolone. Prats G; Rossi V; Salvatori E; Mirelis B Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207 [TBL] [Abstract][Full Text] [Related]
9. Are the quinolones realising their clinical potential? Ball P J Chemother; 1989 Jul; 1(4 Suppl):664-5. PubMed ID: 16312582 [No Abstract] [Full Text] [Related]
10. Quinolones: a comprehensive review. Oliphant CM; Green GM Am Fam Physician; 2002 Feb; 65(3):455-64. PubMed ID: 11858629 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of quinolone-resistant urinary tract infections in Comanche County Memorial Hospital. Siddiqui AA J Okla State Med Assoc; 2008 Sep; 101(9):210-2. PubMed ID: 18856050 [TBL] [Abstract][Full Text] [Related]
12. Treatment of bacterial urinary tract infections: presence and future. Wagenlehner FM; Naber KG Eur Urol; 2006 Feb; 49(2):235-44. PubMed ID: 16413668 [TBL] [Abstract][Full Text] [Related]
13. New agents in development for the treatment of bacterial infections. Abbanat D; Morrow B; Bush K Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and antibacterial activity of quinolone-based compounds containing a coumarin moiety. Emami S; Foroumadi A; Faramarzi MA; Samadi N Arch Pharm (Weinheim); 2008 Jan; 341(1):42-8. PubMed ID: 18072241 [TBL] [Abstract][Full Text] [Related]
16. Tigecycline: a new glycylcycline for treatment of serious infections. Noskin GA Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069 [TBL] [Abstract][Full Text] [Related]
17. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Appelbaum PC; Jacobs MR Curr Opin Microbiol; 2005 Oct; 8(5):510-7. PubMed ID: 16098786 [TBL] [Abstract][Full Text] [Related]
18. Part IX. Quinolone antimicrobials. Vincent S; Machado L; Cooper TW; Bronze MS; Greenfield RA J Okla State Med Assoc; 2007 May; 100(5):149-56. PubMed ID: 17557602 [No Abstract] [Full Text] [Related]
19. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Colodner R; Kometiani I; Chazan B; Raz R Infection; 2008 Feb; 36(1):41-5. PubMed ID: 18193386 [TBL] [Abstract][Full Text] [Related]